A new international study reveals that GLP-1 receptor agonists—commonly used for weight loss—may significantly reduce the risk of dementia in people with type 2 diabetes, outperforming metformin.

USA: A recent study published in JAMA Network Open has found that the use of glucagon-like peptide-1 (GLP-1) receptor ...

The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging ...

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six ...

People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, ...

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

New medicines have made weight loss easier than ever. But if you also want health and happiness, make these seven psychology ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

Clinical practice guidelines provide recommendations for pregnancy care in individuals with preexisting diabetes mellitus.

With the sales of weight-loss drugs booming, India is now the epicentre of the global obesity treatment market, reports The ...